Endocrine Abstracts

Introduction: Aromatase inhibitors, such as Letrozole or Exemestane, are often used as adjuvant treatment for post-menopausal breast cancer. However, they are known to reduce bone mineral density (BMD). Furthermore, breast cancer patients often undergo chemotherapy with drugs associated to BMD loss by themselves. Therefore, patients treated for breast cancer are subject to a considerable risk of BMD loss, and to alleviate this the treatments are normally combined with an anti-...